ADXN
Addex Therapeutics Ltd
Price Chart
Latest Quote
$2.99
+0.09 (+3.10%)
Current Price
| Previous Close | $2.90 |
| Open | $2.91 |
| Day High | $2.99 |
| Day Low | $2.91 |
| Volume | 439 |
Stock Information
Note: Financial values converted from CHF to USD
| Shares Outstanding | 1.75M |
| Total Debt | $93K |
| Cash Equivalents | $925K |
| Revenue | $100K |
| Net Income | $-8.28M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.24M |
| EPS (TTM) | $-7.38 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.48M |
| Sales | $100K |
| Income | $-8.28M |
| Book/sh | $2.18 |
| Cash/sh | $0.44 |
| Employees | 3 |
Financial Ratios
| Quick Ratio | 0.58 |
| Current Ratio | 0.76 |
| Debt/Eq | 4.06 |
Returns & Margins
| ROA | -27.12% |
| ROE | -150.58% |
| Operating Margin | -6487.25% |
Ownership
| Institutional Ownership | 0.02% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -59.80 |
| P/S | 63.08 |
| P/B | 1.37 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $2.99 |
| SMA50 | $3.47 |
| SMA200 | $5.88 |
| RSI | 46.45 |
| ATR | 0.2351 |
| Shares Float | 876K |
| Short Float | 0.12% |
| Short Ratio | 0.05 |
| Volatility | 2.02 |
| Rel Volume | 0.07 |
Performance History
| Week | -1.97% |
| Month | +6.41% |
| Quarter | -49.19% |
| 6 Months | -55.64% |
| YTD | -63.04% |
| Year | -68.85% |
| 3 Years | -54.70% |
| 5 Years | -98.18% |
| 10 Years | -98.68% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $2.99 | 500 |
| 2026-10-26 | $2.90 | 500 |
| 2026-10-23 | $2.97 | 7,500 |
| 2026-10-22 | $2.89 | 1,400 |
| 2026-10-21 | $2.99 | 900 |
| 2026-10-20 | $3.05 | 6,200 |
| 2026-10-19 | $2.89 | 3,500 |
| 2026-10-16 | $2.76 | 11,300 |
| 2026-10-15 | $3.02 | 36,700 |
| 2026-10-14 | $2.65 | 5,200 |
| 2026-10-13 | $3.01 | 1,200 |
| 2026-10-12 | $3.04 | 2,400 |
| 2026-10-09 | $3.22 | 4,500 |
| 2026-10-08 | $3.18 | 11,700 |
| 2026-10-07 | $3.13 | 9,400 |
| 2026-10-06 | $3.18 | 1,700 |
| 2026-10-05 | $3.10 | 5,900 |
| 2026-10-02 | $3.07 | 13,400 |
| 2026-10-01 | $2.98 | 5,700 |
| 2026-09-30 | $2.76 | 5,100 |
| 2026-09-29 | $2.95 | 31,300 |
| 2026-09-28 | $2.81 | 90,700 |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
đ° Latest News
No news articles available at the moment. Check back later for updates on ADXN.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $36,369 | $490,356 | $1,957,230 | $1,726,050 |
| Operating Revenue | $36,369 | $490,356 | $1,957,230 | $1,726,050 |
| Expenses | ||||
| Interest Expense | $2,938 | $4,304 | $4,690 | $33,911 |
| Total Expenses | $3,451,729 | $3,833,679 | $4,678,947 | $14,516,854 |
| Other Income Expense | $-4,884,807 | $-2,620,710 | $-385,008 | $-320,786 |
| Net Non Operating Interest Income Expense | $-2,938 | $6,817 | $72,927 | $1,584 |
| Interest Expense Non Operating | $2,938 | $4,304 | $4,690 | $33,911 |
| Operating Expense | $3,451,729 | $3,833,679 | $4,678,947 | $14,516,854 |
| Other Operating Expenses | $919,765 | $1,039,039 | $1,056,295 | $981,652 |
| General And Administrative Expense | $2,290,899 | $2,032,734 | $2,464,459 | $3,958,287 |
| Rent Expense Supplemental | - | - | $43,159 | $57,375 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,303,104 | $-5,957,217 | $-3,033,798 | $-13,110,006 |
| Net Interest Income | $-2,938 | $6,817 | $72,927 | $1,584 |
| Interest Income | $0 | $11,121 | $77,617 | $35,494 |
| Normalized Income | $-8,287,177 | $-5,978,367 | $-2,648,790 | $-12,789,220 |
| Net Income From Continuing And Discontinued Operation | $-8,164,356 | $8,561,809 | $-12,809,401 | $-25,244,768 |
| Total Operating Income As Reported | $-3,415,360 | $-3,343,324 | $-2,721,717 | $-12,790,804 |
| Net Income Common Stockholders | $-8,164,356 | $8,561,809 | $-12,809,401 | $-25,244,768 |
| Net Income | $-8,164,356 | $8,561,809 | $-12,809,401 | $-25,244,768 |
| Net Income Including Noncontrolling Interests | $-8,164,356 | $8,561,809 | $-12,809,401 | $-25,244,768 |
| Net Income Discontinuous Operations | $138,748 | $14,519,026 | $-9,775,603 | $-12,134,762 |
| Net Income Continuous Operations | $-8,303,104 | $-5,957,217 | $-3,033,798 | $-13,110,006 |
| Pretax Income | $-8,303,104 | $-5,957,217 | $-3,033,798 | $-13,110,006 |
| Earnings From Equity Interest | $-4,868,879 | $-2,641,860 | $0 | $0 |
| Interest Income Non Operating | $0 | $11,121 | $77,617 | $35,494 |
| Operating Income | $-3,415,360 | $-3,343,324 | $-2,721,717 | $-12,790,804 |
| Depreciation Amortization Depletion Income Statement | $10,280 | $233,828 | $14,260 | $10,695 |
| Depreciation And Amortization In Income Statement | $10,280 | $233,828 | $14,260 | $10,695 |
| Depreciation Income Statement | $10,280 | $233,828 | $14,260 | $10,695 |
| Per Share | ||||
| Diluted EPS | $-8.74 | $10.19 | $-20.39 | $-66.98 |
| Basic EPS | $-8.74 | $10.19 | $-20.39 | $-66.98 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,273,958 | $-5,658,421 | $-2,272,844 | $-12,363,192 |
| Total Unusual Items | $-15,928 | $21,150 | $-385,008 | $-320,786 |
| Total Unusual Items Excluding Goodwill | $-15,928 | $21,150 | $-385,008 | $-320,786 |
| Reconciled Depreciation | $10,280 | $315,641 | $371,256 | $392,117 |
| EBITDA (Bullshit earnings) | $-8,289,886 | $-5,637,271 | $-2,657,852 | $-12,683,978 |
| EBIT | $-8,300,166 | $-5,952,912 | $-3,029,108 | $-13,076,095 |
| Diluted Average Shares | $1,085,744 | $992,121 | $751,402 | $831,574 |
| Basic Average Shares | $1,085,744 | $992,121 | $751,402 | $456,912 |
| Diluted NI Availto Com Stockholders | $-8,164,356 | $8,561,809 | $-12,809,401 | $-25,244,768 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $-15,928 | $21,150 | $-385,008 | $-320,786 |
| Research And Development | $230,785 | $528,078 | $1,143,932 | $9,566,220 |
| Selling General And Administration | $2,290,899 | $2,032,734 | $2,464,459 | $3,958,287 |
| Other Gand A | $1,595,509 | $1,464,401 | $1,412,255 | $1,720,309 |
| Insurance And Claims | $223,081 | $273,962 | $762,765 | $1,930,871 |
| Salaries And Wages | $472,309 | $294,371 | $289,439 | $307,106 |
| Rent And Landing Fees | - | - | $43,159 | $57,375 |
Fetched: 2026-10-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,784,119 | $11,742,836 | $1,389,959 | $5,961,547 |
| Total Assets | $7,722,694 | $12,957,533 | $5,632,672 | $10,049,812 |
| Total Non Current Assets | $5,683,956 | $8,660,284 | $494,212 | $549,799 |
| Non Current Prepaid Assets | $8,598 | $8,602 | $65,943 | $65,957 |
| Financial Assets | $617,725 | $0 | - | - |
| Investmentin Financial Assets | $346,999 | $0 | - | - |
| Goodwill And Other Intangible Assets | $0 | $0 | - | - |
| Current Assets | $2,038,738 | $4,297,249 | $5,138,460 | $9,500,014 |
| Prepaid Assets | $19,773 | $205,860 | $263,327 | $328,108 |
| Receivables | $24,374 | $18,824 | $183,555 | $726,024 |
| Accounts Receivable | $24,374 | $18,824 | $133,917 | $505,855 |
| Cash Cash Equivalents And Short Term Investments | $1,994,591 | $4,062,898 | $4,691,578 | $8,445,882 |
| Cash And Cash Equivalents | $1,988,366 | $4,055,015 | $4,690,549 | $8,442,041 |
| Cash Financial | $1,988,366 | $4,055,015 | $4,690,549 | $8,442,041 |
| Other Current Assets | - | $9,668 | - | - |
| Other Receivables | - | - | $49,638 | $220,169 |
| Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $42,092 | $50,957 | $417,833 | $452,779 |
| Long Term Debt And Capital Lease Obligation | $32,773 | $42,092 | $85,402 | $105,604 |
| Current Debt And Capital Lease Obligation | $9,319 | $8,865 | $332,431 | $347,175 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,938,575 | $1,214,697 | $4,242,713 | $4,088,265 |
| Total Non Current Liabilities Net Minority Interest | $483,699 | $241,402 | $731,872 | $105,604 |
| Current Liabilities | $1,454,877 | $973,296 | $3,510,841 | $3,982,661 |
| Payables And Accrued Expenses | $1,445,558 | $964,430 | $2,893,278 | $3,635,486 |
| Payables | $784,726 | $334,837 | $1,394,240 | $1,695,694 |
| Total Tax Payable | $53,139 | $27,483 | $199,744 | $146,675 |
| Accounts Payable | $731,587 | $307,353 | $1,194,496 | $1,549,018 |
| Non Current Deferred Liabilities | - | $0 | $108,278 | $0 |
| Current Deferred Liabilities | - | $0 | $285,133 | $0 |
| Other Payable | - | - | - | $146,675 |
| Equity | ||||
| Common Stock Equity | $5,784,119 | $11,742,836 | $1,389,959 | $5,961,547 |
| Total Equity Gross Minority Interest | $5,784,119 | $11,742,836 | $1,389,959 | $5,961,547 |
| Stockholders Equity | $5,784,119 | $11,742,836 | $1,389,959 | $5,961,547 |
| Other Equity Interest | $78,413,086 | $78,413,086 | $78,413,086 | $78,413,086 |
| Gains Losses Not Affecting Retained Earnings | $38,535,896 | $37,693,237 | $36,178,639 | $31,268,503 |
| Other Equity Adjustments | $38,535,896 | $37,693,237 | $36,178,639 | $31,268,503 |
| Retained Earnings | $-436,950,261 | $-428,785,904 | $-437,347,714 | $-424,538,313 |
| Long Term Equity Investment | $4,669,089 | $8,599,857 | $0 | - |
| Other | ||||
| Treasury Shares Number | $122,227,126 | $104,370,583 | $108,139,682 | $46,370,940 |
| Ordinary Shares Number | $143,098,079 | $119,333,459 | $115,564,359 | $93,597,891 |
| Share Issued | $265,325,205 | $223,704,041 | $223,704,041 | $139,968,831 |
| Tangible Book Value | $5,784,119 | $11,742,836 | $1,389,959 | $5,961,547 |
| Invested Capital | $5,784,119 | $11,742,836 | $1,389,959 | $5,961,547 |
| Working Capital | $583,861 | $3,323,953 | $1,627,619 | $5,517,352 |
| Capital Lease Obligations | $42,092 | $50,957 | $417,833 | $452,779 |
| Total Capitalization | $5,784,119 | $11,742,836 | $1,389,959 | $5,961,547 |
| Treasury Stock | $1,231,622 | $1,055,343 | $1,103,708 | $7,618,934 |
| Additional Paid In Capital | $324,363,767 | $323,240,719 | $323,012,614 | $327,037,516 |
| Capital Stock | $2,653,252 | $2,237,040 | $2,237,040 | $1,399,688 |
| Common Stock | $2,653,252 | $2,237,040 | $2,237,040 | $1,399,688 |
| Employee Benefits | $450,926 | $199,310 | $538,192 | $0 |
| Non Current Pension And Other Postretirement Benefit Plans | $450,926 | $199,310 | $538,192 | $0 |
| Long Term Capital Lease Obligation | $32,773 | $42,092 | $85,402 | $105,604 |
| Current Capital Lease Obligation | $9,319 | $8,865 | $332,431 | $347,175 |
| Current Accrued Expenses | $660,831 | $629,594 | $1,499,038 | $1,939,793 |
| Investments And Advances | $5,016,088 | $8,599,857 | $0 | - |
| Available For Sale Securities | $346,999 | - | - | - |
| Investmentsin Associatesat Cost | $4,669,089 | $8,599,857 | $0 | - |
| Net PPE | $41,545 | $51,825 | $428,268 | $483,842 |
| Accumulated Depreciation | $-196,797 | $-186,516 | $-5,244,204 | $-4,872,948 |
| Gross PPE | $238,341 | $238,341 | $5,672,472 | $5,356,789 |
| Leases | $135,471 | $135,471 | $2,093,389 | $1,786,009 |
| Other Properties | $102,870 | $102,870 | $3,569,904 | $3,561,602 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $6,225 | $7,883 | $1,029 | $3,841 |
| Non Current Deferred Revenue | - | $0 | $108,278 | $0 |
| Current Deferred Revenue | - | $0 | $285,133 | $0 |
| Machinery Furniture Equipment | - | $0 | $9,178 | $9,178 |
Fetched: 2026-10-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,634,531 | $-6,522,057 | $-9,706,654 | $-19,946,325 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,634,531 | $-6,520,512 | $-9,698,351 | $-19,945,620 |
| Cash Flow From Continuing Operating Activities | $-2,634,531 | $-6,520,512 | $-9,698,351 | $-19,945,620 |
| Operating Gains Losses | $4,721,373 | $-14,393,468 | $-76,014 | $-13,825 |
| Investing Activities | ||||
| Investing Cash Flow | $-825,976 | $5,636,708 | $-8,302 | $3,606 |
| Cash Flow From Continuing Investing Activities | $-825,976 | $5,636,708 | $-8,302 | $3,606 |
| Capital Expenditure | - | $-1,545 | $-8,302 | $-705 |
| Net Other Investing Changes | - | $-574,287 | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-35,008 | $-31,285 | $-58,307 | $-4,231 |
| Issuance Of Capital Stock | $1,491,000 | $292,318 | $2,852,217 | $2,033,571 |
| Financing Cash Flow | $1,436,554 | $127,312 | $6,388,298 | $3,764,941 |
| Cash Flow From Continuing Financing Activities | $1,436,554 | $127,312 | $6,388,298 | $3,764,941 |
| Net Other Financing Charges | $-7,635 | $11,121 | $12,576 | $-634,768 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $1,455,992 | $261,033 | $2,793,910 | $2,029,340 |
| Common Stock Issuance | $1,491,000 | $292,318 | $2,852,217 | $2,033,571 |
| Other | ||||
| Repayment Of Debt | $-8,865 | $-89,416 | $-341,940 | $-349,564 |
| End Cash Position | $1,988,366 | $4,055,015 | $4,690,549 | $8,442,041 |
| Beginning Cash Position | $4,055,015 | $4,690,549 | $8,442,041 | $24,857,222 |
| Effect Of Exchange Rate Changes | $-42,696 | $120,959 | $-433,137 | $-238,108 |
| Changes In Cash | $-2,023,953 | $-756,492 | $-3,318,356 | $-16,177,072 |
| Interest Paid Cff | $-2,938 | $-11,187 | $-26,219 | $-59,334 |
| Proceeds From Stock Option Exercised | $0 | $-44,239 | $3,949,971 | $2,779,267 |
| Common Stock Payments | $-35,008 | $-31,285 | $-58,307 | $-4,231 |
| Net Issuance Payments Of Debt | $-8,865 | $-89,416 | $-341,940 | $-349,564 |
| Net Long Term Debt Issuance | $-8,865 | $-89,416 | $-341,940 | $-349,564 |
| Long Term Debt Payments | $-8,865 | $-89,416 | $-341,940 | $-349,564 |
| Net Investment Purchase And Sale | $-964,724 | $0 | $0 | $4,311 |
| Purchase Of Investment | $-964,724 | $0 | $0 | - |
| Net Business Purchase And Sale | $138,748 | $6,212,540 | $0 | $0 |
| Sale Of Business | $138,748 | $6,212,540 | $0 | - |
| Net PPE Purchase And Sale | $0 | $-1,545 | $-8,302 | $-705 |
| Purchase Of PPE | $0 | $-1,545 | $-8,302 | $-705 |
| Change In Working Capital | $666,602 | $-1,490,559 | $259,381 | $191,332 |
| Change In Other Current Assets | $11,325 | $-16,521 | $2,812 | $16,964 |
| Change In Payables And Accrued Expense | $474,741 | $-1,390,710 | $-744,091 | $-518,612 |
| Change In Prepaid Assets | $186,087 | $-199,350 | $64,781 | $1,025,337 |
| Change In Receivables | $-5,550 | $162,619 | $542,468 | $-332,357 |
| Changes In Account Receivables | $-5,550 | $112,980 | $371,938 | $-305,897 |
| Other Non Cash Items | $131,570 | $486,065 | $2,556,426 | $4,729,523 |
| Depreciation Amortization Depletion | $10,280 | $315,641 | $371,256 | $392,117 |
| Depreciation And Amortization | $10,280 | $315,641 | $371,256 | $392,117 |
| Depreciation | $10,280 | $315,641 | $371,256 | $392,117 |
| Pension And Employee Benefit Expense | $-8,759 | $-115,543 | $-76,014 | $-13,825 |
| Earnings Losses From Equity Investments | $4,868,879 | $2,641,860 | $0 | $0 |
| Gain Loss On Sale Of Business | $-138,748 | $-16,919,786 | $0 | $0 |
| Net Income From Continuing Operations | $-8,164,356 | $8,561,809 | $-12,809,401 | $-25,244,768 |
| Sale Of Investment | - | $0 | $0 | $4,311 |
| Purchase Of Business | - | $-574,287 | $0 | $0 |
| Change In Other Working Capital | - | $-46,598 | $393,411 | - |
| Stock Based Compensation | - | - | - | $4,467,993 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-10-25